SELARL PHARMACIE BISCHOFF : revenue, balance sheet and financial ratios

SELARL PHARMACIE BISCHOFF is a French company founded 10 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in GUEBWILLER (68500), this company of category PME shows in 2020 a revenue of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE BISCHOFF (SIREN 818212680)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C 1 940 443 € N/C 2 054 138 € 1 937 512 €
Net income 13 636 € 6 685 € 79 722 € 120 415 € 42 421 € 30 142 € 58 665 € 64 372 €
EBITDA N/C N/C N/C N/C 67 772 € N/C 74 569 € 137 055 €
Net margin N/C N/C N/C N/C 2.2% N/C 2.9% 3.3%

Revenue and income statement

In 2024, SELARL PHARMACIE BISCHOFF generates positive net income of 14 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 64 k€ -> 14 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

13 636 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 256%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 25%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

256.207%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

24.892%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

41.1%

Solvency indicators evolution
SELARL PHARMACIE BISCHOFF

Sector positioning

Debt ratio
256.21 2024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average

In 2024, the debt ratio of SELARL PHARMACIE BISCHOFF (256.21) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
24.89% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Watch

In 2024, the financial autonomy of SELARL PHARMACIE BISCHOFF (24.9%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 106.43. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

106.433

Liquidity indicators evolution
SELARL PHARMACIE BISCHOFF

Sector positioning

Liquidity ratio
106.43 2024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Watch -22 pts over 3 years

In 2024, the liquidity ratio of SELARL PHARMACIE BISCHOFF (106.43) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 62 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 953 days. Excellent situation: suppliers finance 891 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

62 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

953 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE BISCHOFF

Positioning of SELARL PHARMACIE BISCHOFF in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELARL PHARMACIE BISCHOFF is estimated at 190 368 € (range 132 569€ - 284 802€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
132k€ 190k€ 284k€
190 368 € Range: 132 569€ - 284 802€
NAF 5 année 2024

Valuation method used

Net Income Multiple
13 636 € × 14.0x = 190 369 €
Range: 132 570€ - 284 802€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE BISCHOFF with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE BISCHOFF

What is the revenue of SELARL PHARMACIE BISCHOFF ?

The revenue of SELARL PHARMACIE BISCHOFF in 2020 is 1.9 M€.

Is SELARL PHARMACIE BISCHOFF profitable?

Yes, SELARL PHARMACIE BISCHOFF generated a net profit of 14 k€ in 2024.

Where is the headquarters of SELARL PHARMACIE BISCHOFF ?

The headquarters of SELARL PHARMACIE BISCHOFF is located in GUEBWILLER (68500), in the department Haut-Rhin.

Where to find the tax return of SELARL PHARMACIE BISCHOFF ?

The tax return of SELARL PHARMACIE BISCHOFF is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE BISCHOFF operate?

SELARL PHARMACIE BISCHOFF operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.